Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2022-12-02 Board/Management Inform…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Valberedningen utsedd i Ascelia Pharma AB inför årsstämman 2023
Board/Management Information Classification · 99% confidence The document is a press release dated December 2, 2022, announcing the composition of the Nomination Committee (Valberedningen) for the upcoming Annual General Meeting (Årsstämman) scheduled for May 4, 2023. The content focuses entirely on the appointment of committee members representing major shareholders and outlines the committee's mandate (proposing board members, remuneration, auditors, etc.). This type of announcement, which concerns the preparatory steps for the AGM, falls under the category of AGM Information, as it directly relates to the proceedings and governance leading up to the Annual General Meeting. It is not the AGM presentation itself, but the preparatory announcement, making AGM-R the most appropriate fit among the specific options, although it is a pre-AGM announcement rather than the meeting material itself. Given the options, AGM-R covers materials related to the AGM.
2022-12-02 Swedish
Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of the Nomination Committee in preparation for the Annual General Meeting (AGM) scheduled for May 4, 2023. It details the committee members, their appointing shareholders, and the duties related to the AGM (proposing board members, fees, auditor election). This content is directly related to the governance and preparation for the AGM. While it mentions the AGM, it is not the meeting presentation itself (AGM-R) nor is it a proxy solicitation document (PSI). It is a specific announcement regarding the preparatory committee for the AGM. Given the options, this falls under general corporate governance related to the AGM process, but the most specific fit for announcements related to shareholder meetings and related preparatory bodies, especially when not a full proxy or voting result, is often captured by AGM-R if it's directly about the meeting structure, or RNS if it's a general regulatory update. Since the core subject is the 'Nomination Committee appointed for AGM 2023', AGM-R is the most appropriate category for materials directly concerning the structure and preparation for the Annual General Meeting.
2022-12-02 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the 9-month period (9M) of 2022 for Ascelia Pharma. It contains detailed financial tables (income statement, cash flow, liquidity), management commentary (VD-ord), and operational updates regarding clinical trials and pipeline status. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2022
2022-11-04 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 9M 2022' and covers the period from January to September. It contains detailed financial tables (Key Ratios Group), management commentary (CEO Comments), and operational updates regarding clinical trials and business strategy. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2022
2022-11-04 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALVÅRSRAPPORT 2022' (Half-Year Report 2022) and covers the period January–June 2022. It contains comprehensive financial data, including income statements, cash flow, and key performance indicators, as well as detailed management commentary on clinical trials (Orviglance, Oncoral), operational updates, and future outlooks. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2022
2022-08-18 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR REPORT 2022' and covers the period 'January – June 2022'. It contains comprehensive financial data, including key ratios for the group, operating results, earnings per share, and cash flow, alongside detailed management commentary on clinical trials, business strategy, and outlook. As it is a comprehensive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report. H1 2022
2022-08-18 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.